Thymalin
Russian thymic bioregulator; regional clinical literature exists, little independent Western validation.
Updated:
Affiliate link to this product’s page on Peptira. We may earn a commission at no extra cost to you. Code KAREL. Disclosure
Quick summary
Thymalin is a thymus peptide preparation developed in the Khavinson school. It was investigated as an immunomodulator in immunosenescence and infections. Related components include dipeptides like Thymogen (Glu-Trp). It is not the same as Thymosin alpha-1 (see its profile).
Studied for
How it works
Proposed to regulate gene expression in immune cells and restore thymic indices in models/regional clinics. Fine molecular mechanism is less characterized than Western immune drugs.
What the research says
The line of bioregulator peptides associated with Vladimir Khavinson proposes dipeptides/tripeptides called “cytomedins” with tissue-specific gene action. There are systematic reviews and regional clinical trials (Russia/Eastern Europe), often from the same circle of authors. Independent Western replication is limited. Treat the evidence as regional / of low external certainty, not as global multicenter RCTs.
Evidence level
C–D — regional clinical + preclinical; low external certainty
What's most reported
- Improvement of immune parameters in regional series
- Geroprotective interest (claims from the school)
Common side effects
Poorly detailed in Western sources; generally described as well-tolerated in the group's literature — possible bias.
Combines / does not combine
Do not confuse or duplicate with TA-1 / Thymagen / Vilon without criteria. No validated Western stacks.
Frequently asked questions
No. Different molecule/preparation and different evidence base.
There is no approved Western drug-type program.
Keep exploring
Keep learning
Related peptides
Educational content. Not medical advice or usage guidelines. Research products are not approved medications unless otherwise indicated.